Skip to main content

European Gram Negative Antibacterial Engine

Objective

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, and drastically increase the risk of complications with a fatal outcome. Antimicrobial resistance, however, is an unavoidable consequence of antibiotic use and therefore new, effective antibacterials will always be needed and once developed should be used carefully, avoiding the overuse which can drive resistance. Despite the recognized need for new antimicrobials for clinical use, the reality is that only two new classes of antibiotics have been brought to market in the last 30 years and many drug developers have left the field. This urgency is especially true when considering resistant Gram-negative infections where carbapenem-resistance is rising and use of drugs of last resort, such as colistin, is increasing. The New Drugs 4 Bad Bugs (ND4BB) initiative is a series of programmes designed to directly address some of the scientific challenges associated with antibacterial drug discovery and development. The ND4BB ENABLE consortium will meet the challenges ahead by creating and optimising a portfolio of new antibiotics ranging from Hits through Phase 1 clinical studies.

The overarching goals of the ENABLE consortium are to: 1) create a drug discovery platform with the expertise and resource base to prosecute multiple antibacterial programmes in parallel; and 2) increase the overall pipeline in the antibacterial area by applying this platform to optimise a variety of antibacterial programmes. More specifically the key objectives of the consortium are designed to increase the overall pipeline of high quality, novel mode of action medicines to treat serious systemic Gram-negative infections by identifying three antibacterial Leads, two antibacterial Candidates and progressing at least one compound into preclinical and Phase 1 clinical studies.

The platform group is made up of academics and SMEs from across Europe with the diverse expertise including from clinical microbiology, in vivo pharmacology, computational and medicinal chemistry, ADME profiling, PKPD modelling, pharmaceutics, assay development and screening all needed to undertake this programme. This group, coupled with additional expertise and advice from within the EFPIA partners, will bring an unrivalled focus and breadth of judgment to this important area of research.

The programmes are coming from institutions across Europe, initially with seven efforts from public partners, and arising from a novel discovery stage alliance between GSK and Sanofi. These initial programmes to be considered for ENABLE cover a diverse landscape of targets and approaches including natural products, PNA-peptides, synthetic small molecules, and follow ups / improvements to medicines already available. In addition, soon after initiation, ENABLE will launch an open call for additional efforts to create a sustainable portfolio of antibacterial discovery programmes moving forward.

The ENABLE consortium will provide a unique opportunity for a productive collaboration between leading European academic researchers, SMEs and the pharmaceutical industry. We believe these interactions will be synergistic for everyone concerned. Bringing together different disciplines for the common goals outlined in this proposal will make Europe the world-leader in antimicrobial drug discovery. The creation of a cooperative environment in the lifetime of this project and beyond will fulfill the needs of European society in the battle against antibiotic resistance and make a sustainable impact on the future of antibacterial drug discovery.

Field of science

  • /social sciences/economics and business/economics/sustainable economy
  • /medical and health sciences/basic medicine/medicinal chemistry
  • /medical and health sciences/clinical medicine/clinical microbiology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/antibiotic resistance

Call for proposal

IMI-JU-08-2012
See other projects for this call

Funding Scheme

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinator

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
Address
Great West Road 980
TW89GS Brentford
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Principal investigator
Neil Pearson (Dr)
Administrative Contact
Neil Pearson (Dr)

Participants (44)

UPPSALA UNIVERSITET
Sweden
EU contribution
€ 25 292 193
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Anna Lobell (Ph D)
CARDIFF UNIVERSITY
United Kingdom
EU contribution
€ 1 275 588
Address
Newport Road 30-36
CF24 ODE Cardiff
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Keith Sexton (Dr)
Inspiralis Ltd
United Kingdom
EU contribution
€ 207 168
Address
Norwich Research Park, Colney
NR4 7UH Norwich
Administrative Contact
Alison Howells (Mrs)
JOHN INNES CENTRE
United Kingdom
EU contribution
€ 1 978 399
Address
Norwich Research Park Colney
NR4 7UH Norwich
Activity type
Research Organisations
Administrative Contact
Mary Anderson (Dr)
KeytoLead AB

Participation ended

Sweden
EU contribution
€ 3 721
Address
Forskargatan
151 36 Sodertalje
Administrative Contact
Jan Blid (Dr)
LATVIJAS ORGANISKAS SINTEZES INSTITUTS
Latvia
EU contribution
€ 6 065 220
Address
Aizkraukles 21
1006 Riga
Activity type
Research Organisations
Administrative Contact
Kārkle Dace (Ms)
MOLECULAR DISCOVERY LTD
United Kingdom
EU contribution
€ 455 910
Address
Marsh Road 215 Pinner
HA5 5NE London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martin Bohl (Dr)
National Medicines Institute (Narodowy Instytut Lekow)
Poland
EU contribution
€ 288 000
Address
Chelmska
00-725 Warsaw
Activity type
Research Organisations
Administrative Contact
Renata Cellmar (Ms)
OT Chemistry
Sweden
EU contribution
€ 2 314 926
Address
Virdings Allé
754 50 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Fredrik Lehmann (Dr)
SP PROCESS DEVELOPMENT AB
Sweden
EU contribution
€ 3 395 700
Address
Po Box 857
501 15 Boras
Activity type
Research Organisations
Administrative Contact
Christine Svärd (Ms)
REGION HOVEDSTADEN
Denmark
EU contribution
€ 1 770 000
Address
Kongens Vaenge 2
3400 Hillerod
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Klaus Tofting (Mr)
STICHTING VU
Netherlands
EU contribution
€ 1 636 530
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Bart Van Leijen (Dr)
KOBENHAVNS UNIVERSITET
Denmark
EU contribution
€ 1 710 018
Address
Norregade 10
1165 Kobenhavn
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karsten Fey Kristiansen (Mr)
HELSINGIN YLIOPISTO
Finland
EU contribution
€ 1 030 230
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tiina Berg (Ms)
SERVICIO MADRILENO DE SALUD
Spain
EU contribution
€ 586 800
Address
Plaza Carlos Trias Bertran 7
28020 Madrid
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
José Ignacio Flores Nicolás (Mr)
MPS Hamburg GmbH

Participation ended

Germany
Address
Kieler Strasse
22769 Hamburg
Administrative Contact
Christa Möhring (Dr)
BEACTICA THERAPEUTICS AB
Sweden
EU contribution
€ 169 699
Address
Virdings Alle 2
754 50 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Per Källblad (Dr)
European Biotechnology Network aisbl
Belgium
EU contribution
€ 285 240
Address
Avenue Tervueren
1040 Brussels
Administrative Contact
Heike Kempas (Ms)
UNIVERSITE DE LIEGE
Belgium
EU contribution
€ 27 580
Address
Place Du 20 Aout 7
4000 Liege
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Isabelle HALLEUX (Dr)
UNIVERSITAT DE BARCELONA
Spain
EU contribution
€ 44 340
Address
Gran Via De Les Corts Catalanes 585
08007 Barcelona
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Xavier Gutierrez (Head of Management Unit)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 1 242 753
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gill Wells (Ms)
BIOMOL-INFORMATICS SL

Participation ended

Spain
Address
Calle Faraday -Parque Cientifico-
28049 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Paulino Gomez-Puertas (Dr.)
ASTON UNIVERSITY
United Kingdom
EU contribution
€ 318 946
Address
Aston Triangle
B4 7ET Birmingham
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karen Woodhall (Dr)
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS
Spain
EU contribution
€ 54 953
Address
Calle Serrano 117
28006 Madrid
Activity type
Research Organisations
Administrative Contact
MaríaÁngeles López Vázquez (Ms.)
Northern Antibiotics Oy
Finland
EU contribution
€ 115 994
Address
Eskolantie
FIN-00720 Helsinki
Administrative Contact
Timo Vaara (Mr.)
FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA
Spain
EU contribution
€ 187 940
Address
Avda Del Conocimiento 3
18100 Armilla Granada
Activity type
Research Organisations
Administrative Contact
Diego Pozas (-)
Redx Pharma Ltd
United Kingdom
EU contribution
€ 583 724
Address
Crown Street
L69 7ZB Liverpool
Administrative Contact
Stephen Smith (Mr)
ASCLEPIA OUTSOURCING SOLUTIONS BVBA
Belgium
EU contribution
€ 480 802
Address
Damvalleistraat 49
9070 Destelbergen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frederik Deroose (Dr)
Basilea Pharmaceutica Ltd
Switzerland
Address
Grenzacherstrasse 487
4058 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Laurenz Kellenberger (Dr.)
ASTRAZENECA AB
Sweden
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eva Lindgren (Senior Director)
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
France
Address
Pierre Brossolette 1
91380 Chilly Mazarin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Olivier Brun (MS & Chemistry Engineer)
The Research Network Ltd.
United Kingdom
EU contribution
€ 441 597
Address
Ramsgate Road
CT13 9NJ Sandwch
Administrative Contact
Andrew Brian McElroy (CEO)
NOSOPHARM
France
EU contribution
€ 1 850 092
Address
21 Avenue Georges-pompidou, Immeuble Danica B
69486 Lyon Cedex 03
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Philippe Villain-Guillot (Dr.)
Bioresources Technology & Engineering GmbH
Germany
EU contribution
€ 86 580
Address
Gutfleischstr.
35390 Giessen
Administrative Contact
Daniela Mueller (Dipl.Ing. (FH))
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 384 438
Address
Ramistrasse 71
8006 Zürich
Activity type
Other
Administrative Contact
Andrea Wagner (-)
Helperby Therapeutics Ltd
United Kingdom
EU contribution
€ 398 748
Address
Lincoln's Inn Fields
WC2A 3LH London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ann Savell (Mrs)
Juvabis GmbH
Switzerland
EU contribution
€ 24 880
Address
Mettlenstrasse
6363 Furigen
Administrative Contact
Gunter Festel (Dr.)
ST GEORGE'S HOSPITAL MEDICAL SCHOOL
United Kingdom
EU contribution
€ 311 800
Address
Cranmer Terrace
SW17 0RE London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jane Boland (Miss)
Spero Europe Limited
United Kingdom
EU contribution
€ 41 460
Address
Wayside Park, Catteshall Lane
GU7 1XE Godalming, Surrey
Administrative Contact
Steve Garbacz (VP, Finance and Operations)
THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
United Kingdom
EU contribution
€ 552 669
Address
North Street 66 College Gate
KY16 9AJ St Andrews
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Trish Starrs (Mrs)
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany
EU contribution
€ 448 562
Address
Inhoffenstrasse 7
38124 Braunschweig
Activity type
Research Organisations
Administrative Contact
Birgit Gerstel (Dr.)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 364 224
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
Administrative Contact
Pascaline TOUTOIS (Ms)
FORSCHUNGSZENTRUM BORSTEL
Germany
EU contribution
€ 567 678
Address
Parkallee 1-40
23845 Borstel
Activity type
Research Organisations
Administrative Contact
Sandra von Pein (Staff)
Mutabilis
France
EU contribution
€ 1 904 898
Address
Rue De Grenelle
75007 Paris
Administrative Contact
Ibrahima Guillard (M)